<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1330">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397523</url>
  </required_header>
  <id_info>
    <org_study_id>ITM05/2020MKD</org_study_id>
    <nct_id>NCT04397523</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of COVID-19 Convalescent Plasma</brief_title>
  <official_title>Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Transfusion Medicine of RNM</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Clinic for Infectious Diseases, North Macedonia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Transfusion Medicine of RNM</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2
      infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are currently no proven therapeutic options for coronavirus disease (COVID-19), the
      infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human
      convalescent plasma is an option for treatment of COVID-19. Experience from prior outbreaks
      with other coronaviruses, such as SARS-CoV-1, MERS and H1N1 shows that convalescent plasma
      can be effective. A plasmapheresis donation will be performed in subjects who recovered from
      COVID-19 and who are otherwise eligible for plasma donation according to the Institutional
      protocol. Recipients will be COVID-19 patients requiring hospitalization. A blood-type
      matched transfusion of convalescent plasma will be infused and recipients will be followed
      up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2020</start_date>
  <completion_date type="Anticipated">April 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of oxygenation and ventilation support</measure>
    <time_frame>28 days after transfusion or until hospital discharge (whichever comes first)</time_frame>
    <description>The total number of days patients required respiratory support.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital length of stay (LOS)</measure>
    <time_frame>28 days after transfusion or until hospital discharge (whichever comes first)</time_frame>
    <description>Total number of days patients were admitted to the hospital.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU admission</measure>
    <time_frame>28 days after transfusion or until hospital discharge (whichever comes first)</time_frame>
    <description>Total number of subjects to be admitted to the ICU after the convalescent plasma transfusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>28 days after transfusion or until hospital discharge (whichever comes first)</time_frame>
    <description>Days without oxygenation support after receiving convalescent plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>28 days after transfusion or until hospital discharge (whichever comes first)</time_frame>
    <description>Cumulation incidence of serious adverse events during the study protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of respiratory support</measure>
    <time_frame>28 days after transfusion or until hospital discharge (whichever comes first)</time_frame>
    <description>Type of supplemental oxygen support (e.g. nasal canula, high flow nasal canula, noninvasive ventilation, intubation and invasive mechanical ventilation, rescue ventilation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with different clinical outcomes including death, critical illness and recovery</measure>
    <time_frame>28 days after transfusion or until hospital discharge (whichever comes first)</time_frame>
    <description>Number of participants with different clinical outcomes including death, critical illness and recovery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Convalescent Plasma</condition>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>Hospitalized patients with SARS CoV-2 infection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-SARS-CoV-2 convalescent plasma</intervention_name>
    <description>Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection</description>
    <arm_group_label>Hospitalized patients with SARS CoV-2 infection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Blood donors:

          1. Age: &gt;18 and &lt;60 years

          2. Body weight : &gt;60 kg

          3. Confirmed previous SARS CoV-2 infection

          4. Two negative SARS CoV-2 test result

          5. 21 day without symptoms from the second negative SARS CoV2 negative test

          6. Written informed consent to participate in this clinical trial, to donate plasma and
             to store the specimen for future testing.

          7. Concentration of COVID-19 IgG antibodies more than 5 AU/ml (Because measurement of
             neutralizing antibody titers is not available now, storing of retention sample from
             the convalescent plasma donation is performed for determining antibody titers at a
             later date)

          8. Male donors, or female donors who have not been pregnant, or female donors who have
             been pregnant tested negative for HLA antibodies

          9. Individuals who meet all regular voluntary donor eligibility requirements

        Patients/recipients:

          1. Age: &gt;18 years

          2. Admitted to an acute care facility for the treatment of COVID-19 complications

          3. Patients with severe or immediately life-threatening COVID-19, or

          4. Patients who are judged by a healthcare provider to be at high risk of progression to
             severe or life-threatening disease.

          5. Informed consent provided by the patient or healthcare proxy

        Exclusion Criteria:

        Blood donors:

          1. Age : &lt;18 or &gt;60 years

          2. Female subjects who are pregnant

          3. HIV1,2 hepatitis B,C or syphilis infection

          4. Donors ineligible for regular voluntary blood donation

        Patients/recipients:

          1. Age : &lt;18 years

          2. Contraindication to transfusion (severe volume overload, history of anaphylaxis to
             blood products)

          3. Patients who received in the past 30 days immunoglobulin therapy

          4. Females who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rada Grubovic Rastvorceva, MD MSci PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Transfusion Medicine of RNM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sedulla Useini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Transfusion Medicine of RNM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rada Grubovic Rastvorceva, MD MSci PhD</last_name>
    <phone>+38923226923</phone>
    <phone_ext>126</phone_ext>
    <email>drgrubovic@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Transfusion Medicine of RNM</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>North Macedonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rada Grubovic Rastvorceva, MD MSci PhD</last_name>
      <phone>+38923226923</phone>
      <phone_ext>126</phone_ext>
      <email>drgrubovic@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>North Macedonia</country>
  </location_countries>
  <link>
    <url>https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds</url>
    <description>Investigational COVID-19 Convalescent Plasma - Emergency INDs - April 03, 2020</description>
  </link>
  <reference>
    <citation>Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 Apr;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27.</citation>
    <PMID>32113510</PMID>
  </reference>
  <reference>
    <citation>Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.</citation>
    <PMID>32219428</PMID>
  </reference>
  <reference>
    <citation>Huaxia, (2020). 'China puts 245 COVID-19 patients on convalescent plasma therapy', Xinhua.net, 2 February. Available at: http://www.xinhuanet.com/english/2020-02/28/c_138828177.htm</citation>
  </reference>
  <reference>
    <citation>Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.</citation>
    <PMID>32167489</PMID>
  </reference>
  <reference>
    <citation>Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA. 2020 Apr 28;323(16):1561-1562. doi: 10.1001/jama.2020.4940.</citation>
    <PMID>32219429</PMID>
  </reference>
  <reference>
    <citation>https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-deviceexemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds Accessed on March 30,2020</citation>
  </reference>
  <reference>
    <citation>Guidance on collection, testing, processing, storage, distribution and monitored use. An EU programme of COVID-19 convalescent plasma collection and transfusion. EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY, 08 April, 2020</citation>
  </reference>
  <reference>
    <citation>AABB's CCP Collection Protocol - Donor Eligibility, Processing, Labeling and Distribution, 03 April, 2020 http://www.aabb.org/advocacy/regulatorygovernment/Documents/COVID-19-Convalescent-Plasma-Collection.pdf</citation>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>anti SARS-CoV-2 convalescent plasma</keyword>
  <keyword>COVID-19 convalescent plasma</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

